The Pitfalls Of Obesity Treatment
While scoring high on Total Body Weight Loss (TBWL%), gold-standard bariatric treatments are avoided by most patients and insurers, as these treatments are highly-invasive, may lead to significant adverse events, and often involve irreversible GI tract reconfigurations. In consequence, they are performed in less than 1% of the eligible population.
Alternatives such as intra-gastric balloons, while utilizing safer trans-oral access and being covered for lower-BMI patients, are temporary and achieve lower TBWL%. Endoscopic gastroplasty, which does provide much higher TBWL%, is an extremely cumbersome procedure that is generally inaccessible to patients and physicians alike.
EndoZip™
An Automated Stitch In Time
EndoZip is a fully automated, operator independent and minimally invasive robotic suturing system,
that safely delivers durable and effective restrictive sutures to the stomach wall.
Shape & Zip. It’s As Simple As That.
Introduce
Trans-oral endoscopic access and positioning directly in the designated area of restriction
Shape
Accurate grasping and stitching of the stomach tissue from within
Zip
Helical needle is activated automatically to connect the stomach walls and secure them with a continuous suture
Remove
Smooth system removal
Simple, Reproducible Procedures
Making safe and effective endoscopic weight-loss treatments accessible to both patients and their physicians.
Consistent Suture Size And Depth
High Suture
Density
High Suture
Durability
Safe and Longer Lasting Effect
Operator
Independent
Reproducible
Results
Ease Of Use With A
Short Learning Curve
Suitable For All Levels of Physician Experience
Clinical Status
Ongoing
An ongoing multi-center pilot study was launched on July 2021 with 45 patients. The study is
showing extremely promising results, demonstrating the high safety profile, very short learning
curve and excellent usability of our robotic suturing system.
Completed
Nitinotes has recently completed its FIH study in Spain. Led by Dr. Lopez Nava,
Director of the Bariatric Endoscopy Unit at HM Sanchinarro University Hospital, Madrid.
About Nitinotes
Nitinotes is a privately-held medical device company based in Caesarea Israel. Its flagship product EndoZip is a novel robotic endoscopic suturing system for safer and simpler gastroscopic restriction for the treatment of obesity. Backed by preclinical success and prominent KOLs, Nitinotes’s fully automated, minimally invasive gastroscopic suturing system provides an effective solution to class 1 and 2 obesity patients, for the majority of whom gold-standard bariatric surgery is uncovered and/or inadvisable.
Nitinotes has completed, in late 2019, its FIH study in Spain, demonstrating a high safety profile with no AE related to the procedure, and achieving promising efficacy results.
An ongoing multi-center pilot study was launched on July 2021 with 45 patients. The study is showing extremely promising results, demonstrating the high safety profile, very short learning curve and excellent usability of our robotic suturing system.
Nitinotes is headed by a team of R&D
and business experts, including:
Raz Bar-On
BSc, MBA
CEO
Irit Yaniv
MD, MBA
Executive Chairwoman
Tal Yered
BSc, MSc
VP R&D
Hagit Ephrath
MA
COO, Regulatory Affairs
Actively Supported by
